Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central side effects, mainly depression and anxiety.

Property Value
dbo:abstract
  • Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central side effects, mainly depression and anxiety. (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-06-21 15:06:06Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 16657658 (xsd:integer)
dbo:wikiPageLength
  • 5086 (xsd:integer)
dbo:wikiPageModified
  • 2019-06-21 12:47:23Z (xsd:date)
dbo:wikiPageOutDegree
  • 19 (xsd:integer)
dbo:wikiPageRevisionID
  • 902814266 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central side effects, mainly depression and anxiety. (en)
rdfs:label
  • Taranabant (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of